Generic Name: Nimotop
What is Nimotop?
When treatment is to be stopped, your prescribing doctor may need to alter the dose of other medication accordingly and monitor your conditionNIMOTOP infusion solution is sensitive to light and should not be exposed to direct sunlight.
Infusion tubes and pumps should be protected from light with coverings, or coloured tubing may be used. The tablets are supplied as blister packs of 100 tablets. Active Ingredients:NIMOTOP tablet - 30 mg nimodipine per tabletNIMOTOP IV - 10 mg nimodipine per 50 mL vialBayer Australia LimitedABN 22 000 138 714875 Pacific HighwayPYMBLE NSW 2073AustraliaBayer New Zealand LimitedArgus Place, Hillcrest,North Shore, AUCKLAND 0627 CMI8515. Utilisation possible quel que soit le terme de la grossesse.
Din aceasta cauza, administrarea concomitenta a sucului de grapefruit si a nimodipinei poate induce concentratii plasmatice crescute de nimodipina si nu este recomandata. Dozare: In cazul in care nu este altfel prescris, se recomanda urmatoarele doze: In hemoragia subarahnoidiana de origine anevrismala: Se recomanda administrarea de Nimotop solutie perfuzabila pentru 5-14 zile, urmata de o doza zilnica de Nimotop 6 x 2 comprimate filmate 6 x 60 mg nimodipina.
In hemoragia subarahnoidiana de origine traumatica: Se recomanda administrarea de Nimotop solutie perfuzabila pentru 7-10 zile, urmata de o doza zilnica de Nimotop 6 x 2 comprimate filmate 6 x 60 mg nimodipina.
Tratamentul tulburarilor cerebrale datorate varstei: Se recomanda o doza zilnica de 3 x 1 comprimat de Nimotop 3 x 30 mg de nimodipina.
Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. The precise mechanism of action of nimodipine in humans is unknown. Although the clinical studies described below demonstrate a favorable effect of nimodipine on the severity of neurological deficits caused by cerebral vasospasm following SAH, there is no arteriographic evidence that the drug either prevents or relieves the spasm of these arteries.
For Consumers What are the possible side effects of nimodipine Nimotop. Strength NDC Code Capsule Identification Unit Dose Package of 100: 30 mg 0026-2855-48 Nimotop Unit Dose Package of 30: 30 mg 0026-2855-70 Nimotop Distributed by: Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516.
Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Nimotop nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition i.
The use of nimodipine in combination with rifampin is contraindicated as efficacy of nimodipine capsules could be significantly reduced when concomitantly administered with rifampin. The concomitant use of oral nimodipine and the antiepileptic drugs phenobarbital, phenytoin or carbamazepine is contraindicated as efficacy of nimodipine capsules could be significantly reduced.
Although treatment with nimodipine has not been shown to be associated with increases in intracranial pressure, close monitoring is recommended in these cases or when the water content of the brain tissue is elevated generalized cerebral edema. Blood Pressure: Nimodipine has the hemodynamic effects expected of a calcium channel blocker, although they are generally not marked.
However, intravenous administration of the contents of Nimotop Capsules has resulted in serious adverse consequences including death, cardiac arrest, cardiovascular collapse, hypotension, and bradycardia.
How should I take Nimotop?
If you miss one or more doses of NIMOTOP tablets, DO NOT TAKE A DOUBLE DOSE. If while undergoing treatment with NIMOTOP you experience any side-effects or symptoms which may be due to this medication whether or not it is mentioned below please inform your Doctor or Pharmacist immediately. Some patients may experience unwanted effects when taking this medication. Uncommon side effects may affect up to 1 in 100 people include dizziness, lightheadedness, nausea, vomiting, allergic reaction, rash, itching, fluid retention,headache, reddening of the face or sweating, thrombocytopaenia decrease in number of platelets in blood.
Ask your doctor, nurse or pharmacist to answer any questions you may have. When treatment is to be stopped, your prescribing doctor may need to alter the dose of other medication accordingly and monitor your conditionNIMOTOP infusion solution is sensitive to light and should not be exposed to direct sunlight. Infusion tubes and pumps should be protected from light with coverings, or coloured tubing may be used.
What should I avoid while taking Nimotop?
Nimodipine relaxes narrowed blood vessels in the brain. This allows blood to flow more easily and so stops the brain being deprived of blood and thus oxygen. This reduces the risk of brain damage after a bleed on the surface of the brain. Certain medicines should not be used during pregnancy or breastfeeding.
However, other medicines may be safely used in pregnancy or breastfeeding providing the benefits to the mother outweigh the risks to the unborn baby.
Nimotop side effects
Where can I get more information. What is nimodipine Nimotop. Nimodipine may also be used for purposes other than those listed here. Side effects other than those listed here may also occur. Contact the applicable plan provider for the most current information. To: By clicking send, you acknowledge that you have permission to email the recipient with this information.
Common Nimotop ide effects may include:
Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy.
Special populations Patients with hepatic impairment Severely disturbed liver function, particularly liver cirrhosis, may result in an increased bioavailability of nimodipine due to a decreased first-pass capacity and a reduced metabolic clearance.
Decreased drug clearance may occur in cirrhotic patients receiving Nimotop and, therefore, close monitoring of blood pressure is recommended in these patients.
Valproic acid The simultaneous administration of the anticonvulsant valproic acid can lead to an increase in the plasma nimodipine concentration.
Upon co-administration with the following inhibitors of the cytochrome P450 3A4 system the blood pressure should be monitored and, if necessary, an adaption in the nimodipine dose should be considered see section 4.
Therefore, macrolide antibiotics should not be used in combination with nimodipine see section 4. Therefore, when administered together with oral nimodipine, a substantial increase in systemic bioavailability of nimodipine due to a decreased first pass metabolism cannot be excluded.
Where can I get more information?
Alcohol and nimodipine may cause low blood pressure, drowsiness, or dizziness.